Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

December 05, 2022; 99 (23 Supplement 2) Abstracts

False Positive Cerebrospinal Fluid NMDA Receptor Antibodies: A Single Center Case Series

Rumyar Ardakani, Steven Vernino, Kyle Blackburn
First published December 5, 2022, DOI: https://doi.org/10.1212/01.wnl.0000903440.65833.71
Rumyar Ardakani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Vernino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle Blackburn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
False Positive Cerebrospinal Fluid NMDA Receptor Antibodies: A Single Center Case Series
Rumyar Ardakani, Steven Vernino, Kyle Blackburn
Neurology Dec 2022, 99 (23 Supplement 2) S54-S55; DOI: 10.1212/01.wnl.0000903440.65833.71

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective To report the presence of CSF NMDA receptor antibodies in four patients without NMDA receptor encephalitis encountered at a single tertiary care center.

Background The diagnosis and confirmation of anti-NMDA encephalitis relies heavily on detection of IgG antibodies to the NR1 subunit of the NMDA receptor in cerebrospinal fluid. While this is generally considered a highly specific test for anti-NMDA encephalitis, there have been rare reports of false positive testing.

Design/Methods A retrospective chart review of medical records for patients with positive CSF NMDA receptor antibody testing at University of Texas Southwestern Medical Center between 2011 to 2021 was performed.

Results 40 patients were identified who had positive CSF NMDA receptor antibodies. Of these 40 patients, 4 (10%) were concluded to have false positive results. The false positive results consisted of 1 patient with refractory status epilepticus from suspected synthetic cannabinoid use, 1 patient with an anaplastic astrocytoma, 1 patient with fungal meningitis from Candida dubliniensis, and 1 patient with bifrontal cerebritis of suspected infectious etiology. Of the 4 patients with false positive antibody testing, 3 were immediately recognized as likely false positives while 1 patient was misdiagnosed and treated for an autoimmune encephalitis prior to a final diagnosis with tissue biopsy.

Conclusions Although uncommon, false positive CSF NMDA receptor antibodies pose significant diagnostic and therapeutic challenges for clinicians. In our case series, false positive tests occurred in patients with apparent central nervous system disorders, including seizure, infection, and neoplasm. While antibody testing is an essential tool for the diagnosis of NMDA receptor encephalitis, caution should be exercised in interpreting positive results when the clinical and paraclinical data are not consistent with the well characterized phenotype of NMDA receptor encephalitis.

Footnotes

  • Disclosure: Dr. Ardakani has nothing to disclose. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LabCorp. The institution of Dr. Vernino has received research support from Grifols. The institution of Dr. Vernino has received research support from Dysautonomia International. The institution of Dr. Vernino has received research support from BioHaven. Dr. Blackburn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech.

  • © 2022 American Academy of Neurology

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • CT
  • Cerebrospinal Fluid
  • Low pressure syndrome

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise